Nurix executives presented the company’s immunology and inflammation pipeline centered on STAT6, BTK and IRAK4 degraders. They emphasized that degraders remove full target proteins, tackling both enzymatic and non-enzymatic scaffolding functions, with assays showing scaffolding-driven signaling can account for up to half of pathway activity.

In partnership with Sanofi, NX-3911 has entered IND-enabling studies with an IND expected this year. High-resolution proteomics revealed exclusive STAT6 degradation at clinically relevant doses, while oral dosing in multiple species, including primates, achieved rapid, potent and complete STAT6 removal, suppressing type 2 inflammatory markers below knockout levels.

Nurix is advancing bexobrutideg in tablet form through Phase 1 multiple ascending dose studies targeting autoimmune, dermatology and neurology indications, with Phase 1 data due later this year. The program builds on oncology findings that BTK scaffolding activity can drive disease even when kinase function is inhibited.

Developed in collaboration with Gilead, Nurix’s IRAK4 degrader demonstrated superior tissue penetration in skin and no observed QT prolongation in preclinical studies. By degrading the entire kinase, the compound aims to deliver deeper inhibition of both catalytic and scaffolding signaling compared to traditional inhibitors.